Leading Companies in the Global Patient Blood Management Market Global Industry Analysis 2025-2034
Author:
Intellectual Market Insights Research
Published Date:
10 Sep 2026
Global Patient Blood Management Market Top Leading Companies
Patient Blood Management (PBM) is an evidence-based, multidisciplinary approach to optimizing the care of patients who might need a blood transfusion, centered on minimizing unnecessary transfusions while improving clinical outcomes. It spans pre-operative anemia management, blood conservation techniques during surgery, cell-salvage and autotransfusion technology, point-of-care coagulation testing, and transfusion-decision support software. As health systems worldwide face pressure to reduce transfusion-related risks and costs while improving surgical outcomes, PBM programs have moved from a niche hospital initiative to a mainstream standard of care.
The global Patient Blood Management market was valued at USD 14 billion in 2025 and is expected to reach USD 22 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.80% from 2024 to 2032. Growth is being driven by rising surgical volumes worldwide, growing awareness of the risks and costs associated with unnecessary blood transfusions, increasing adoption of blood-conservation technologies such as cell salvage and point-of-care coagulation testing, and expanding regulatory and hospital-accreditation support for structured PBM programs.
The competitive landscape brings together specialized blood-management technology providers such as Haemonetics Corporation, Terumo Corporation, and Immucor, alongside diversified global healthcare conglomerates including Fresenius SE & Co. KGaA, Grifols, S.A., and B. Braun Melsungen AG. This article provides a research-based analysis of the top companies shaping the global Patient Blood Management market, their positioning, flagship offerings, and the regional and technological forces driving the industry forward.
Market Overview
|
Parameter |
Details |
|---|---|
|
Market Size (2025) |
USD 14 Billion |
|
Projected Market Size (2034) |
USD 22 Billion |
|
CAGR (2024–2032) |
7.80% |
|
Forecast Horizon |
Through 2034 |
|
Leading Region |
North America (highest revenue share) |
|
Fastest-Growing Region |
Asia-Pacific |
|
Key Segments (by Product) |
Instruments & Systems (Cell Salvage, Apheresis), Consumables & Reagents, Software & Decision-Support Solutions |
|
Key Segments (by Application) |
Surgical Blood Loss Management, Anemia Management, Transfusion & Coagulation Testing |
|
Key Segments (by End User) |
Hospitals, Blood Banks & Transfusion Centers, Ambulatory Surgical Centers |
Why the Patient Blood Management Market Is Growing
1. Rising Global Surgical Volumes
Growing rates of cardiac, orthopedic, and oncologic surgery worldwide are driving sustained demand for blood-conservation technologies and transfusion-management protocols that reduce intraoperative and post-operative blood loss.
2. Growing Awareness of Transfusion-Related Risks and Costs
Hospitals are increasingly focused on minimizing unnecessary blood transfusions given their associated clinical risks and substantial per-unit costs, driving broader adoption of structured PBM programs as a standard of surgical and critical care.
3. Increasing Adoption of Blood-Conservation Technologies
Intraoperative cell-salvage systems, autotransfusion devices, and point-of-care coagulation and hemostasis testing are becoming standard equipment in operating rooms, particularly for high-blood-loss procedures such as cardiac and orthopedic surgery.
4. Expanding Regulatory and Accreditation Support
Growing hospital-accreditation requirements and clinical guidelines favoring formal PBM programs are pushing healthcare systems to adopt integrated blood-management technology and protocols.
5. Growth in Pre-Operative Anemia Management
Increasing recognition of pre-operative anemia as a modifiable risk factor for poor surgical outcomes is driving demand for iron-deficiency screening and treatment programs as a core pillar of PBM strategy.
6. Rising Demand for Transfusion Decision-Support Software
Hospitals are increasingly deploying digital decision-support tools that integrate with electronic health records to guide clinicians toward evidence-based transfusion decisions, reducing variability in transfusion practice.
Market Opportunities & Restraints
A key opportunity lies in digital transfusion decision-support and analytics platforms: software that integrates with hospital electronic health record systems to flag unnecessary transfusion orders and track PBM program performance is opening a growing software and services revenue stream alongside traditional devices and consumables. On the restraint side, the high upfront cost of blood-conservation equipment and the complexity of establishing multidisciplinary PBM programs remain key barriers, particularly for smaller hospitals and healthcare systems in developing regions with constrained capital budgets and limited specialized staffing.
Top 10 Companies in the Patient Blood Management Market
- Haemonetics Corporation
- Fresenius SE & Co. KGaA
- Terumo Corporation
- Grifols, S.A.
- B. Braun Melsungen AG
- bioMérieux, Inc.
- Immucor, Inc.
- Macopharma
- Asahi Kasei Corporation
- LivaNova PLC
1. Haemonetics Corporation
|
Category |
Details |
|---|---|
|
Company Name |
Haemonetics Corporation (NYSE: HAE) |
|
Headquarters |
Boston, Massachusetts, USA |
|
Founded |
1971 |
|
Employees |
Approx. 3,300 |
|
Revenue |
Approx. USD 1.3 Billion |
|
Company Overview |
Haemonetics specializes in blood management solutions spanning plasma and whole-blood collection as well as hospital transfusion services, and is one of the most focused pure-play companies in the PBM space. |
|
Key Products |
Cell-salvage and autotransfusion systems, apheresis platforms for plasma and blood-component collection, and hospital transfusion-management software. |
|
Market Position |
A leading pure-play specialist in blood and plasma management technology, with a strong installed base across hospitals and blood centers worldwide. |
|
Recent Developments |
Continues to expand its hospital-focused blood-management software and device portfolio to support broader adoption of structured PBM programs. |
|
Strategic Advantages |
Deep specialization and decades of engineering focus purely on blood-management technology, plus an established global distribution network across 50+ countries. |
2. Fresenius SE & Co. KGaA
|
Category |
Details |
|---|---|
|
Company Name |
Fresenius SE & Co. KGaA |
|
Headquarters |
Bad Homburg, Germany |
|
Founded |
1912 |
|
Company Overview |
Fresenius is a global healthcare group offering products and services spanning dialysis, hospital care, and outpatient medical services, with blood-management solutions integrated across its hospital-facing businesses. |
|
Key Products |
Dialysis and blood-purification systems, hospital infusion and transfusion equipment, and broader clinical-care products relevant to blood-management protocols. |
|
Market Position |
One of the largest diversified healthcare groups globally, bringing significant scale and hospital-relationship depth into the blood-management space. |
|
Recent Developments |
Continues to integrate blood-management-relevant technology across its dialysis and hospital-care business segments as part of its broader clinical-care portfolio. |
|
Strategic Advantages |
Massive global scale across dialysis and hospital care, extensive existing relationships with hospital systems worldwide, and broad clinical-care product integration. |
3. Terumo Corporation
|
Category |
Details |
|---|---|
|
Company Name |
Terumo Corporation (TYO: 4543) |
|
Headquarters |
Tokyo, Japan |
|
Founded |
1921 |
|
Employees |
Approx. 30,600 (consolidated) |
|
Revenue |
Approx. JPY 1.04 Trillion (FY2024) |
|
Company Overview |
Terumo provides a broad range of medical devices and services, including blood transfusion and cell-therapy technologies, with its Terumo BCT subsidiary specializing in blood-component and apheresis technology. |
|
Key Products |
Apheresis collection systems, whole-blood processing technology, pathogen-reduction systems, and blood transfusion-related devices through its Terumo BCT business. |
|
Market Position |
A leading global medical-device manufacturer with strong depth in blood-component and cell-therapy technology through its dedicated Terumo BCT subsidiary. |
|
Recent Developments |
Continues to expand its apheresis and cell-therapy technology portfolio through Terumo BCT to support blood-component collection and processing worldwide. |
|
Strategic Advantages |
Century-long medical-device manufacturing heritage, strong global distribution, and dedicated blood-technology expertise through its Terumo BCT subsidiary. |
4. Grifols, S.A.
|
Category |
Details |
|---|---|
|
Company Name |
Grifols, S.A. (Nasdaq: GRFS) |
|
Headquarters |
Sant Cugat del Vallès, Barcelona, Spain |
|
Founded |
1909 |
|
Employees |
Approx. 23,800+ |
|
Revenue |
Approx. EUR 7.2 Billion (2024) |
|
Company Overview |
Grifols specializes in the production of plasma-derived medicines and transfusion medicine, and is one of the world's largest plasma-products companies serving over 110 countries. |
|
Key Products |
Plasma-derived therapeutics, transfusion-medicine diagnostic solutions, and tools and services supporting hospitals, pharmacies, and blood centers. |
|
Market Position |
A global leader in plasma-derived medicines and transfusion medicine, with deep expertise across the blood-products supply chain. |
|
Recent Developments |
Continues expanding its plasma-collection network and transfusion-medicine diagnostic offerings to support global demand for plasma-derived therapies. |
|
Strategic Advantages |
Vertically integrated plasma-collection and manufacturing operations, over a century of transfusion-medicine expertise, and a direct presence in more than 30 countries. |
5. B. Braun Melsungen AG
|
Category |
Details |
|---|---|
|
Company Name |
B. Braun Melsungen SE |
|
Headquarters |
Melsungen, Germany |
|
Founded |
1839 |
|
Employees |
Approx. 63,000+ |
|
Revenue |
Approx. EUR 8.76 Billion (2023) |
|
Company Overview |
B. Braun offers products and services spanning anesthesia, intensive care, cardiology, and surgery, including blood-management solutions integrated across its hospital-facing product lines. |
|
Key Products |
Infusion and transfusion systems, surgical and intensive-care equipment, and blood-management-relevant consumables used across hospital settings. |
|
Market Position |
One of the largest family-owned medical-device companies globally, with broad hospital-product integration relevant to blood-management workflows. |
|
Recent Developments |
Continues to expand its hospital and surgical product portfolio, with blood-management-relevant offerings integrated across its broader clinical-care business. |
|
Strategic Advantages |
Nearly two centuries of medical-device manufacturing heritage, broad product breadth across surgical and critical care, and a global manufacturing footprint in 60+ countries. |
Competitive Landscape
The global Patient Blood Management market brings together specialized blood-technology pure-plays such as Haemonetics, Immucor, and Macopharma, which compete primarily on deep technical focus in transfusion, apheresis, and diagnostic technology. Diversified global healthcare conglomerates, including Fresenius, Grifols, B. Braun, Terumo, Asahi Kasei, and bioMérieux, bring broader scale and integrated hospital-product portfolios that embed blood-management solutions within larger clinical-care businesses. Cardiac and surgical-technology specialists such as LivaNova round out the landscape, competing on integration of blood-conservation technology with broader surgical and cardiac-care product lines.
Regional Analysis
North America
North America holds the largest share of the global Patient Blood Management market, supported by high surgical volumes, strong hospital-accreditation frameworks favoring structured PBM programs, and the concentrated presence of leading blood-management technology providers such as Haemonetics.
Europe
Europe represents a mature, steadily growing market, underpinned by strong regulatory support for transfusion-medicine standards and the presence of major manufacturers including Fresenius, B. Braun, and Grifols, all headquartered within the region.
Asia-Pacific
Asia-Pacific is expected to be the fastest-growing region, driven by rising surgical volumes, expanding hospital infrastructure, and growing awareness of blood-conservation practices across China, Japan, and India, supported by strong regional players such as Terumo and Asahi Kasei.
Latin America & Middle East and Africa
Latin America and the Middle East & Africa remain developing Patient Blood Management markets, expected to grow steadily as hospital infrastructure investment and surgical-care capacity expand across these regions.
Emerging Trends in the Patient Blood Management Market
1. Growth of Digital Transfusion Decision-Support Software: Hospitals are increasingly deploying EHR-integrated decision-support tools that guide clinicians toward evidence-based transfusion decisions and track PBM program performance.
2. Expansion of Point-of-Care Coagulation Testing: Rapid, bedside coagulation and hemostasis testing devices are becoming standard in operating rooms, enabling real-time, targeted blood-product administration rather than empiric transfusion.
3. Rising Focus on Pre-Operative Anemia Management: Structured iron-deficiency screening and treatment programs ahead of elective surgery are becoming a core pillar of comprehensive PBM strategy.
4. Broader Adoption of Cell-Salvage and Autotransfusion Technology: Intraoperative blood-recovery systems are expanding beyond cardiac and orthopedic surgery into a wider range of high-blood-loss procedures.
5. Growing Integration of PBM into Hospital Accreditation Standards: Regulatory bodies and accreditation organizations are increasingly embedding PBM program requirements into hospital quality standards, accelerating institutional adoption.
Future Outlook (2025–2034)
The global Patient Blood Management market's trajectory toward USD 22 billion by 2034 reflects sustained demand growth driven by rising surgical volumes and the ongoing shift toward evidence-based, cost-conscious transfusion practices. The 7.80% CAGR forecast assumes continued expansion of blood-conservation technology adoption, growing regulatory and accreditation support for structured PBM programs, and increasing integration of digital decision-support tools into hospital transfusion workflows.
Key investment themes include continued growth of transfusion decision-support software, expansion of point-of-care coagulation testing, and broader adoption of cell-salvage technology across a wider range of surgical procedures. Specialized players such as Haemonetics are likely to retain strong positions built on deep technical focus, while diversified healthcare conglomerates including Fresenius, Grifols, B. Braun, and Terumo continue to leverage broad hospital relationships and integrated clinical-care portfolios across the global market.
Frequently Asked Questions (FAQ)
1. What is the current size of the global Patient Blood Management market?
The global Patient Blood Management market was valued at USD 14 billion in 2025 and is expected to reach USD 22 billion by 2034, growing at a CAGR of 7.80%.
2. Who are the top companies in the Patient Blood Management market?
Leading companies include Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, Grifols, S.A., B. Braun Melsungen AG, bioMérieux, Inc., Immucor, Inc., Macopharma, Asahi Kasei Corporation, and LivaNova PLC.
3. Which region dominates the Patient Blood Management market?
North America currently holds the largest market share, while Asia-Pacific is expected to be the fastest-growing region, driven by rising surgical volumes and expanding hospital infrastructure.
4. What is the forecast CAGR for the Patient Blood Management market?
The market is forecast to grow at a CAGR of 7.80% between 2024 and 2032, supporting continued expansion toward USD 22 billion by 2034.
5. What are the main growth drivers for this market?
Key drivers include rising global surgical volumes, growing awareness of transfusion-related risks and costs, increasing adoption of blood-conservation technologies, and expanding regulatory and accreditation support for structured PBM programs.
6. What technologies are used in Patient Blood Management?
PBM programs commonly rely on intraoperative cell-salvage and autotransfusion systems, point-of-care coagulation testing, pre-operative anemia screening and treatment, and digital transfusion decision-support software.
7. Are pure-play specialists or diversified companies stronger in this market?
The market includes both models: pure-play specialists such as Haemonetics compete on deep technical focus, while diversified healthcare conglomerates such as Fresenius, Grifols, B. Braun, and Terumo leverage broad hospital relationships and integrated clinical-care portfolios.
Conclusion
The global Patient Blood Management market sits at the intersection of rising surgical demand and the healthcare industry's ongoing shift toward safer, more cost-conscious transfusion practices. With a projected size of USD 22 billion by 2034 growing at a 7.80% CAGR, the market offers steady, clinically-driven growth across hospitals and blood centers worldwide.
Haemonetics continues to lead as a focused pure-play specialist in blood-management technology, while diversified global healthcare groups such as Fresenius, Grifols, B. Braun, and Terumo bring scale, broad hospital relationships, and integrated clinical-care portfolios into the space. As digital decision-support software, point-of-care testing, and expanding cell-salvage adoption reshape the industry, the companies that combine deep transfusion-technology expertise with strong hospital-system integration will define market leadership through 2034 and beyond.
